IL142629A0 - Improved chemical process and pharmaceutical formulation - Google Patents

Improved chemical process and pharmaceutical formulation

Info

Publication number
IL142629A0
IL142629A0 IL14262999A IL14262999A IL142629A0 IL 142629 A0 IL142629 A0 IL 142629A0 IL 14262999 A IL14262999 A IL 14262999A IL 14262999 A IL14262999 A IL 14262999A IL 142629 A0 IL142629 A0 IL 142629A0
Authority
IL
Israel
Prior art keywords
manufacturing
substituted sulphinyl
compound
formula
adjusted
Prior art date
Application number
IL14262999A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL142629(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9803952A external-priority patent/SE9803952D0/xx
Priority claimed from SE9803953A external-priority patent/SE9803953D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL142629A0 publication Critical patent/IL142629A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
IL14262999A 1998-11-18 1999-11-15 Improved chemical process and pharmaceutical formulation IL142629A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9803952A SE9803952D0 (sv) 1998-11-18 1998-11-18 Pharmaceutical formulation
SE9803953A SE9803953D0 (sv) 1998-11-18 1998-11-18 Improved chemical process
PCT/SE1999/002093 WO2000028975A2 (en) 1998-11-18 1999-11-15 Improved chemical process and pharmaceutical formulation

Publications (1)

Publication Number Publication Date
IL142629A0 true IL142629A0 (en) 2002-03-10

Family

ID=26663439

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14262999A IL142629A0 (en) 1998-11-18 1999-11-15 Improved chemical process and pharmaceutical formulation
IL142629A IL142629A (en) 1998-11-18 2001-04-16 Improved chemical process for the preparation of basic salt of an acid-sensitive proton pump inhibitor and a process for the preparation of a pharmaceutical preparation containing the compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142629A IL142629A (en) 1998-11-18 2001-04-16 Improved chemical process for the preparation of basic salt of an acid-sensitive proton pump inhibitor and a process for the preparation of a pharmaceutical preparation containing the compound

Country Status (18)

Country Link
US (1) US6403616B1 (ko)
EP (1) EP1131316B1 (ko)
JP (1) JP4610086B2 (ko)
KR (1) KR100619200B1 (ko)
CN (1) CN100503598C (ko)
AT (1) ATE271556T1 (ko)
AU (1) AU770633B2 (ko)
BR (1) BR9915421A (ko)
CA (1) CA2347981C (ko)
DE (1) DE69918854T2 (ko)
DK (1) DK1131316T3 (ko)
ES (1) ES2222754T3 (ko)
HK (1) HK1038920B (ko)
IL (2) IL142629A0 (ko)
NO (1) NO321275B1 (ko)
NZ (1) NZ511169A (ko)
PT (1) PT1131316E (ko)
WO (1) WO2000028975A2 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP3372080A3 (en) 2011-11-10 2018-10-17 Rotam Agrochem International Co., Ltd Herbicidal composition and method of using the same
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76839A (en) 1984-10-31 1988-08-31 Byk Gulden Lomberg Chem Fab Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
EP0519144B1 (en) 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
TNSN95062A1 (fr) 1994-05-27 1996-02-06 Astra Ab Nouveaux derives dialkoxy-pyridinyle-benzimidazole
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
AUPN846496A0 (en) * 1996-03-05 1996-03-28 Research Laboratories Of Australia Pty Ltd Electronic printing for display technology
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
CN1145802C (zh) * 1996-05-17 2004-04-14 福姆法克特公司 微电子弹簧接触元件及电子部件
CN1128997C (zh) * 2001-01-04 2003-11-26 中国科学院南京土壤研究所 一种吸力平板的制作方法

Also Published As

Publication number Publication date
CN1326455A (zh) 2001-12-12
ATE271556T1 (de) 2004-08-15
EP1131316B1 (en) 2004-07-21
BR9915421A (pt) 2001-08-07
KR100619200B1 (ko) 2006-09-05
NZ511169A (en) 2003-06-30
WO2000028975A3 (en) 2000-08-10
DE69918854T2 (de) 2005-07-21
HK1038920B (zh) 2005-03-11
CA2347981A1 (en) 2000-05-25
US6403616B1 (en) 2002-06-11
KR20010089474A (ko) 2001-10-06
ES2222754T3 (es) 2005-02-01
NO321275B1 (no) 2006-04-10
PT1131316E (pt) 2004-10-29
IL142629A (en) 2007-12-03
NO20012427D0 (no) 2001-05-16
JP2002529497A (ja) 2002-09-10
CA2347981C (en) 2010-05-04
WO2000028975A2 (en) 2000-05-25
CN100503598C (zh) 2009-06-24
DE69918854D1 (de) 2004-08-26
HK1038920A1 (en) 2002-04-04
NO20012427L (no) 2001-07-09
EP1131316A2 (en) 2001-09-12
AU1901700A (en) 2000-06-05
DK1131316T3 (da) 2004-09-27
AU770633B2 (en) 2004-02-26
JP4610086B2 (ja) 2011-01-12

Similar Documents

Publication Publication Date Title
IL142629A0 (en) Improved chemical process and pharmaceutical formulation
NZ527585A (en) Tablets quickly disintegrated in oral cavity
CS261851B2 (en) Process for preparing 2-pyridylmethylsulphinylbenzimidazoles
BR0009176A (pt) Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
CA2370692A1 (en) Antitumor derivative of double dicarboxylic acid diaminoplatin complex, process for the preparing thereof, the pharmaceutical composition containing the same and application of the derivative
MY131971A (en) Formulation of substituted benzimidazoles
JP2002529497A5 (ko)
US4585782A (en) Azole derivatives antimycotic agents which release the active compounds at a relatively high rate
MY115018A (en) New process for the preparation of ropivacaine hydrochloride monohydrate
MX9703339A (es) Solucion acuosa para infusion, estable al almacenamiento, que contiene un inhibidor de trombina.
MXPA04005210A (es) Procedimiento para la preparacion de composiciones que tienen una cantidad incrementada de sales farmaceuticamente activas de rotameros.
AR029002A1 (es) Proceso para preparar compuestos de acidos quinolin-2-carboxilicos y de sus sales farmaceuticamente aceptables
NZ505080A (en) Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid
IL168882A (en) Imidazole derivatives having affinity for alpha 2 receptor activity
NZ584037A (en) Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
EP2264025B1 (en) Method for producing lansoprazole
Challis et al. The chemistry of nitroso compounds. Part 13. Decomposition of N-nitroso-2-pyrrolidone under basic conditions, an unusual example of nucleophilic catalysed hydrolysis of an amide derivative
CN103172544A (zh) 一种精氨酸布洛芬结晶物的制备方法
SU1189876A1 (ru) Дезинфицирующее средство "дезнор
GB1188959A (en) 2-Substituted Pyridines as Anthelmintic Agents
RU2190411C2 (ru) Инъекционная форма препарата, проявляющего противоишемическую активность
TH12553B (th) ริสเพอริโดนพาโมเอท
GB1244026A (en) Antibacterial agents and process for their preparation
GB1156854A (en) Lactones of Optically Active Heterocyclic Amino Acids and Process for the Preparation thereof
MXPA05004842A (es) Formulacion oromucosal y proceso para su preparacion.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed